Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -40

Zoetis (NYSE:ZTS) Misses Q1 CY2026 Revenue Estimates, Stock Drops 13%

AI-generated analysis

πŸ“‰ Zoetis missed Q1 CY2026 revenue expectations, reporting $2.26 billion in sales versus analyst estimates of $2.31 billion.

πŸ“ˆ The company reported year-on-year revenue growth of 1.9%, which was significantly lower than its five-year trend.

πŸ’° Adjusted EPS of $1.53 came in 5.3% below the consensus estimate of $1.62, marking a miss on Wall Street's profit projections.

⚠️ Zoetis lowered its full-year revenue guidance to a midpoint of $9.82 billion, representing a 0.8% decrease from analyst estimates and a 1.1% drop from prior guidance.

πŸ“‰ Management also reduced its full-year Adjusted EPS guidance to $6.93 at the midpoint, down 1.8% from earlier projections.

πŸ”½ Operating margins contracted to 33.5% in Q1 from 38.1% a year ago, as expenses grew faster than revenue.

⚠️ Analysts expect Zoetis's annualized revenue growth of 6.3% over the last five years to be considered mediocre compared to the broader healthcare sector.

πŸ“‰ Revenue growth decelerated to 4.3% over the last two years, falling below the company's longer-term five-year trend.

πŸ”Ž The gap between EPS growth (9.2% CAGR) and revenue growth (6.3%) was driven by stock buybacks rather than operational efficiency improvements.

πŸ’Έ Zoetis repurchased stock over the past five years, shrinking its share count by 11.6%, which boosted per-share earnings without increasing top-line sales.

πŸ“‰ The company's stock price dropped approximately 13% immediately after releasing its disappointing Q1 results, falling to $96.81.

πŸ‘€ While newer products are expected to help sustain future growth, the current quarter highlighted slowing demand and changing consumer tastes in the pet health sector.

Bullish Signals
  • Zoetis remains the world's largest pure-play animal health company with a strong portfolio of medicines, vaccines, diagnostic products, and services for pets and livestock globally.
  • Analysts expect revenue to grow 5.2% over the next 12 months, a projection above average for the healthcare sector that indicates confidence in sustaining top-line performance.
  • The company maintains an elite operating margin of approximately 38.1% averaged over the last five years, demonstrating its efficient cost structure and economies of scale.
  • Zoetis has successfully repurchased stock, shrinking its share count by 11.6%, which boosts per-share earnings and shows a commitment to returning capital to shareholders.
Risk Factors
  • Zoetis missed Wall Street's revenue expectations for Q1 CY2026 with sales rising only 1.9% year on year to $2.26 billion versus analyst estimates of $2.31 billion.
  • The company also underperformed on profitability, reporting non-GAAP profit of $1.53 per share which is 5.3% below consensus estimates.
  • Zoetis lowered its full-year revenue guidance to $9.82 billion at the midpoint from a previous expectation of $9.93 billion, representing a 1.1% decrease.
  • Management reduced its full-year Adjusted EPS guidance to $6.93 at the midpoint, marking an 1.8% decrease.
  • Operating margins contracted significantly to 33.5% in Q1 from 38.1% the prior year, indicating a decline of 4.6 percentage points due to expenses outpacing revenue growth.
  • The company's recent annualized revenue growth of 4.3% over the last two years is below its five-year trend, signaling potential deceleration in demand.
  • Analysts anticipate the stock will continue to struggle, as sell-side forecasts project only 5.2% revenue growth over the next 12 months compared to higher analyst expectations.
Full Analysis
Zoetis (NYSE:ZTS), a global animal health company spun off from Pfizer in 2013, reported disappointing Q1 CY2026 financial results that led to an immediate 13% stock decline to $96.81. The company's Q1 revenue of $2.26 billion represented only 1.9% year-over-year growth, missing Wall Street estimates of $2.31 billion, while its non-GAAP profit per share dropped to $1.53, failing to meet the consensus expectation of $1.62. Consequently, the company also lowered its full-year revenue guidance from $9.93 billion to $9.82 billion and adjusted its EPS guidance down 1.8% to a midpoint of $6.93. The report highlights significant concerns regarding Zoetis's operational efficiency and long-term growth trajectory. Although the company has historically maintained elite profitability with an average adjusted operating margin of 38.1% over the past five years, the current quarter saw that margin contract sharply to 33.5%, a decline of 6.4 percentage points year-over-year. Management indicated that expenses grew faster than revenue, undermining previous economies of scale. Furthermore, the article argues that Zoetis's historical outperformance in earnings per share relative to revenue growth has largely been driven by stock repurchases rather than organic operational improvement, with share count shrinking by 11.6% over five years. Looking ahead, analysts project revenue growth of 5.2% for the coming 12 months, which is comparable to the company's two-year trend but below its long-term five-year average of 6.3%. The article suggests that this deceleration signals potential shifts in demand cycles or consumer tastes within the animal health sector. Despite the stock trading down significantly after the earnings miss, the author concludes that a single quarter does not define long-term business quality but notes a lack of immediate positives given the combined miss in revenue and EPS estimates alongside reduced guidance.